Biogen (NASDAQ: BIIB) today announced the addition of two members to the executive management team of Bioverativ Inc., Biogen's planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations officer of Bioverativ, and John T. Greene will serve as executive vice president and chief financial officer of Bioverativ. The spin-off of Bioverativ is on track to be completed in early 2017. "Biogen is committed to positioning Bioverativ for success as it prepares to carry forward our dedication to the hemophilia community," remarked George A. Scangos, Ph.D., chief executive officer of Biogen. "Rogerio and John will be instrumental players in that success, alongside the rest of the executive team." "Rogerio's expertise in the industry and extensive knowledge of the rare disease space will be critical as we work to deliver transformative medicines to patients," said John Cox, chief executive officer of Bioverativ. "And, given John's strong track record of fiscal and operational management across all of the major disciplines within finance, I am confident in his ability to lead our global finance organization and be an excellent representative for our shareholders." Dr. Vivaldi has more than 20 years of experience in delivering orphan products to patients worldwide, most notably during his tenure at Genzyme Corp., where he applied his medical and professional expertise to lead the company's rare disease business and earned a reputation as a passionate advocate for patients. Most recently, he served as chief commercial officer at Spark Therapeutics, a gene therapy company, and was co-founder, president and CEO of Minerva Neurosciences. He received his medical degree from Universidade do Rio de Janeiro Medical School, and completed his residency in endocrinology at Universidade do Estado do Rio de Janeiro and his fellowship at Mount Sinai Hospital Center in New York in the department of genetics. He received his MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro.